Cancer Tools Help Roche Push Ahead With Alzheimer’s Drug

Roche Holding AG (ROG) is focusing part of its pipeline on the riskiest area of drug development: the human brain.

The Swiss drugmaker had its last top-selling brain therapy when Valium revolutionized anxiety treatment in the 1960s. Now Roche is betting it can use the tools that have since made it the world’s biggest maker of cancer drugs to penetrate the “black box” of Alzheimer’s and autism, Chief Executive Officer Severin Schwan said.

“If you think back 15 years, a cancer tumor was like a black box,” Schwan said in an interview at the company’s Basel headquarters. “The brain has been a black box until recently. And now we start to understand what is happening on a molecular basis in the brain.”

The stakes are different now than when Valium inventor Leo Sternbach was cooking up his new class of medicines. Roche’s brain drugs are just one component in a late-stage pipeline packed with risky projects, said Karl Heinz Koch, a Helvea SA analyst. Treatments for central nervous system diseases also have an “enormous” potential payoff, said Andrew Baum, a London-based analyst for Citigroup Inc.

“The central nervous system will remain the highest of the high-hanging fruit,” Baum said in an interview.

A hint of whether the gamble may pay off is due in the second half of this year. Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE) plan to announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug, called gantenerumab. If the therapy from Indianapolis-based Lilly succeeds, its sales may exceed $9 billion a year by 2020, according to analysts at Sanford C. Bernstein Ltd.

Path to Approval

The path to patients may be rockier than Valium’s. Sternbach’s anxiety drug took just five years to progress from the test tube to its approval in 1963. That’s less than half as long as the process is likely to take under current testing standards, which are more stringent, according to Tufts Center for the Study of Drug Development research.

Roche needs new pipeline prospects after the failure this month of a good-cholesterol pill that UBS AG analysts estimated might have had peak sales of $6.8 billion.

“For the company to create value medium- to longer-term, you need the ex-oncology business to take shape,” Koch said in an interview. Yet investors have even lower expectations for Roche’s central nervous system pipeline than they did for the cholesterol drug, he said. “That pipeline is just very risky.”

Schizophrenia Drug

The Roche brain drug furthest along in the patient testing process, a schizophrenia medicine, didn’t have statistically significant results in an earlier trial if all patients who entered the trial were measured, Koch said. The compound had an effect on patients who stuck with it and who followed study protocols perfectly.

The Swiss drugmaker is also running clinical trials on treatments for depression and autism. Meanwhile, the field of Alzheimer’s, where four of Roche’s 10 brain drugs in patient testing are concentrated, is littered with failures.

The last new therapy for Alzheimer’s was Namenda, a medicine from New York-based Forest Laboratories Inc. (FRX) approved in 2003, according to data compiled by Bloomberg. Namenda, like all other Alzheimer’s drugs on the market, addresses symptoms without slowing the disease’s march through the brain.

Lilly’s solanezumab, which is similar to Roche’s Alzheimer’s drug, has at most a one-in-five chance of success, according to Bernstein’s Anderson. Lilly said on April 25 that one final-stage trial of the drug had finished that month, with a second slated to complete in June. The first look at the results could come in July, Anderson said in a note to clients.

Brain Protein

Both the Lilly and Roche medicines target a reduction in beta amyloid, a protein that accumulates in the brains of Alzheimer’s patients. New York-based Pfizer, Johnson & Johnson (JNJ), based in New Brunswick, New Jersey, and Dublin-based Elan Corp. (ELN) are also expecting to release results in the third quarter for a drug to target beta amyloid, bapineuzumab, and have said they’ll seek regulators’ approval by the end of the year if it’s successful.

The cloud hanging over all three drugs is the earlier failure of a Lilly drug called semagacestat, which tried to zap beta amyloid by inhibiting an enzyme called gamma secretase that’s tied to the production of the protein. The pill actually worsened patients’ ability to do day-to-day activities, Lilly said in 2010. The U.S. company gave up on the medicine that year.

Lilly has said that semagacestat failed not because beta amyloid isn’t the right target, but because gamma secretase wasn’t the right way to go after the protein.

Failure Expected

Still, investors expect both the new Lilly and Pfizer drugs to fail just as the older Lilly compound did. Two-thirds of 209 analysts and fund managers in a survey conducted last month by New York-based ISI Group thought neither would succeed in this year’s trials.

“There was a lot of hope riding on these types of approaches,” said Cord Dohrmann, chief scientific officer of Evotec AG (EVT), a German biotech working with Roche on another therapy for the disease. “There was no obvious success. People are wondering, are we really on the right track.”

The Evotec-partnered drug started out with Roche, which licensed the compound to Evotec in 2006. The Hamburg, Germany- based biotech tested it unsuccessfully as an anti-smoking drug. After it failed to help smokers quit, Roche signed a deal last September to finish developing the drug in Alzheimer’s instead.

Original Plan

“The original plan was always Alzheimer’s,” Dohrmann said. Smoking was an easier indication for a small biotech to pursue, with shorter, less expensive clinical trials, he said. And the drug did show itself to be safe -- an important characteristic, he said.

By taking the drug back, Roche gave itself a candidate that doesn’t go after beta amyloid, he said. Instead it targets monoamine oxidase type B, or MAO-B, an enzyme that breaks down dopamine in the brain and contributes to the production of free radicals.

“It is such a wide-open market,” Dohrmann said. “People have made estimates that just slowing progression for a year would have a huge economic impact. That is saying a lot for a disease that people have for many, many years.”

Roche is forging ahead with beta amyloid as well. Gantenerumab isn’t as far along in the testing process as the Lilly and Pfizer drugs -- it’s in the second of the three stages of clinical trials usually required for regulatory approval in the U.S. Roche is recruiting patients for a two-year, 360-person trial. If that’s successful, the company will test the compound in a larger patient group, with the aim of having it on the market after 2016.

Genetic Tests

One thing that may give Roche an advantage is its experience in drugs that work alongside genetic tests to show doctors which patients are most likely to benefit, said Luca Santarelli, the company’s head of neuroscience. About half the Roche brain drugs in human testing have some sort of personalized health-care strategy, Santarelli said. Roche has identified a genetic marker and is working on a companion diagnostic for its schizophrenia drug, he said.

“We think like oncologists do, in terms of pathways, mechanisms, targets,” the chain of events that have led to the disease itself, Santarelli said in an interview in Basel. “It still is a leap of faith. In science, there’s always a point where you take a risk on the biology because the biology is not fully understood.”

Not From Genentech

Still, Roche’s top-selling cancer medicines came from Genentech Inc., the California biotech it first invested in when the company was a startup and acquired fully in 2009. The central nervous system pipeline will be a test for the Swiss company’s own labs.

Investors could see a payoff as soon as 2013. That’s when bitopertin, the experimental schizophrenia treatment, would reach the market if it succeeds in its final trial.

“Wait until the end of the year or early next year for bapineuzumab,” Santarelli said. “Then they’ll start paying attention.”

To contact the reporter on this story: Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.